Eloxx Pharmaceuticals (NASDAQ:ELOX) vs. Artiva Biotherapeutics (NASDAQ:ARTV) Financial Contrast

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and Artiva Biotherapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals $6.36 million 6.87 -$5.99 million ($1.54) -6.94
Artiva Biotherapeutics $250,000.00 748.37 -$83.86 million ($2.98) -1.27

Eloxx Pharmaceuticals has higher revenue and earnings than Artiva Biotherapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Eloxx Pharmaceuticals has a beta of -1918.69, suggesting that its stock price is 191,969% less volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Eloxx Pharmaceuticals and Artiva Biotherapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals 1 1 3 2 2.86
Artiva Biotherapeutics 1 4 2 0 2.14

Eloxx Pharmaceuticals presently has a consensus price target of $37.33, suggesting a potential upside of 249.24%. Artiva Biotherapeutics has a consensus price target of $24.80, suggesting a potential upside of 555.22%. Given Artiva Biotherapeutics’ higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Eloxx Pharmaceuticals.

Profitability

This table compares Eloxx Pharmaceuticals and Artiva Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals N/A -93.20% -46.80%
Artiva Biotherapeutics N/A -45.32% -41.38%

Institutional and Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats Artiva Biotherapeutics on 8 of the 14 factors compared between the two stocks.

About Eloxx Pharmaceuticals

(Get Free Report)

Eloxx Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on compounds intended to help cells produce functional proteins when a genetic mutation prematurely stops protein production. The company’s lead investigational candidate, ELX-02, was designed to promote ribosomal readthrough of these premature stop signals. Eloxx studied the candidate for conditions including cystic fibrosis and nephropathic cystinosis in patients with relevant genetic mutations.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.